910629-24-2

Basic information

• Product Name: (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol
• CAS NO: 910629-24-2
• Molecular Weight: 192.258
• Mol File: 910629-24-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 320.0±15.0 °C(Predicted)
• Density: 1.104±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol(910629-24-2)
• EPA Substance Registry System: (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol(910629-24-2)

Safety Data

• Hazardous Substances Data: 910629-24-2(Hazardous Substances Data)

Usage

Description

(R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is a chiral chemical compound with the molecular formula C13H16O2. It features a tetrahydro-2H-pyran-4-yl group, a phenyl group, and a methanol group, which are significant functional groups in organic chemistry. (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is widely recognized for its versatile reactivity and is predominantly utilized as an intermediate in the synthesis of pharmaceuticals and natural products.

Uses

Used in Pharmaceutical Industry:
(R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is used as an intermediate for the synthesis of various pharmaceuticals and natural products. Its unique structure and functional groups make it a valuable building block in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is used as a key component in the synthesis of complex organic molecules. Its versatile reactivity allows for the creation of a wide range of compounds with potential applications in drug discovery and development.
Used in Natural Product Synthesis:
(R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is also employed in the synthesis of natural products, which are often sought after for their biological activities and potential use in the pharmaceutical industry. Its chiral nature and functional groups enable the creation of diverse natural product analogs with potential therapeutic properties.

Upstream product

• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 639468-72-7 phenyl(tetrahydro-2H-pyran-4-yl)methanone 
• 3174-74-1 dihydropyran 
• 100-52-7 benzaldehyde 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 216087-92-2 rac-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 100-58-3 phenylmagnesium bromide 
• 100-59-4 phenylmagnesium chloride 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 

Downstream Products

• 1800340-40-2 (-)-(S)-2-[3-(dimethyl-1H-1, 2,3-triazo1-5-yl)-5-[oxan-4-yl(phenyl)-methyl]-5H-pyrido [3,2-b] indol-7-yl]propan-2-ol 

Relevant articles and documents

Development of BET inhibitors as potential treatments for cancer: A search for structural diversity

We describe our efforts to identify structurally diverse leads in the triazole-containing N1-carboline series of bromodomain and extra-terminal inhibitors. Replacement of the N5 “cap” phenyl moiety with various heteroaryls, coupled with additional modifications to the carboline core, provided analogs with similar potency, improved pharmacokinetic properties, and increased solubility compared to our backup lead, BMS-986225 (2). Rapid SAR exploration was enabled by a convergent, synthetic route. These efforts provided a potent BET inhibitor, 3-fluoropyridyl 12, that demonstrated robust efficacy in a multiple myeloma mouse tumor model at 1 mg/kg.

SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF

Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.